Accretive Acquisition
An accretive acquisition raises the buyer's earnings per share: the target's earnings, plus synergies, less the cost of the financing, add more to the buyer's profit than the shares issued or the interest paid take away. It is the test listed acquirers announce first, because it is what analysts ask, and it is a test of financing arithmetic as much as of value — a deal can be accretive and still destroy it.
- Also known as
- Accretion, EPS-accretive deal, Accretive deal, EPS accretion
- Used at
- every listed-company acquisition announcement ("accretive to EPS in the first full year"), and in the buyer's board paper before it
- Binding
- no — a forecast; but a board that promised accretion and delivered dilution explains it to shareholders
- Typical arithmetic
- a deal is accretive when the target's earnings yield (earnings ÷ price paid) exceeds the buyer's cost of the financing — the after-tax interest rate on debt, or the buyer's own earnings yield if paying in shares; so a buyer on 20× earnings buying a target at 12× with shares is accretive, and the same buyer at 10× buying at 12× is dilutive
- Typical caveat
- accretion measures earnings, not value; buying a low-growth business at a low multiple is accretive and may be a poor use of capital; buying a fast-growing fintech at a high multiple is dilutive and may be the right deal
- Parties
- the buyer's board, its shareholders and analysts; the target, whose price is set partly by what the buyer can absorb
How accretion works in practice
A buyer with 100m shares earning €200m — €2.00 a share — considers a target earning €30m. If it pays €360m (12× earnings) in cash borrowed at 5%, the after-tax interest is about €13.5m and the group's earnings rise to €216.5m on the same 100m shares: €2.17 a share, accretive. If instead it issues shares at its own price of €40 (20× earnings), it issues 9m shares; earnings become €230m on 109m shares, €2.11, still accretive, because its shares are dearer than the target's. If the buyer's shares traded at €20 (10×), it would issue 18m shares and earn €230m on 118m: €1.95, dilutive — the same target, the same price, a different answer.
The arithmetic explains behaviour. Buyers with high-multiple shares use them as currency and grow by accretive acquisition — the roll-up model — until their multiple falls. Buyers with cheap debt make cash deals accretive that share deals are not. And a target priced above the buyer's multiple is dilutive on day one whatever its merits, which is why banks (on 10× earnings) struggle to buy fintechs (on 30×) and why such deals are justified by synergies and growth, not accretion.
The limit of the test is that it ignores what was paid for the earnings: an accretive deal at a fair price creates value; an accretive deal that overpays for a business whose earnings will fall is accretive for a year and then explains itself.
Example
A listed bank earning €400m on 200m shares (€2.00; shares at €24, 12×) buys a payments fintech earning €40m for €800m — 20× — half in cash at 4.5% after tax, half in new shares. Interest costs €18m; 16.7m new shares are issued. Year-one earnings: €400m + €40m + €10m of synergies − €18m = €432m on 216.7m shares: €1.99 — dilutive by a cent. Year three, with the fintech's earnings at €60m and synergies at €25m: €467m on 216.7m shares, €2.16 — accretive. The bank announces "dilutive in year one, accretive from year two", its shares fall 3% on the day, and the board's paper had said all of this: the deal was for growth the bank's own book could not produce, at a price accretion could never flatter.
Common mistakes
- Treating accretion as proof a deal creates value; it proves the financing was cheaper than the target's earnings yield. - Announcing year-one accretion built on synergies that arrive in year three. - Issuing undervalued shares to buy a target because the cash alternative "looks dilutive". - Ignoring the earnings the target will lose after the deal — customers, key people — in the accretion model. - Judging a fintech acquisition on accretion at all, when the case is growth and the buyer's multiple is the wrong yardstick.